Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.

Advertisement

Related Content

Deal Watch: Biogen Picks Up S1P Modulator To Try Competing With Novartis, Celgene
Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal
Merck Continues Manufacturing Site Divestment With Sale Of Pavia, Italy, Factory
Deal Watch: Teva Boosts CNS Portfolio With $3.2 Billion Purchase Of Auspex
Evotec Drug Development Strategy Offers Little Downside, Big Upside

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel